TY - JOUR
T1 - Recent advances in mantle cell lymphoma
T2 - Report of the 2013 Mantle Cell Lymphoma Consortium Workshop
AU - Gordon, Leo I.
AU - Bernstein, Steven H.
AU - Jares, Pedro
AU - Kahl, Brad S.
AU - Witzig, Thomas E.
AU - Dreyling, Martin
N1 - Funding Information:
This meeting, as well as some of the projects presented, was supported by grants from the Lymphoma Research Foundation Mantle Cell Lymphoma Initiative and the MCL Consortium. Meeting support was provided by the LRF and by Celgene Corporation, Janssen, Millennium: The Takeda Oncology Company and Pharmacyclics. The work summarized in this report has been supported in part by LRF Mantle Cell Lymphoma Initiative grants.
Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.
AB - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.
KW - Immunotherapy
KW - Lymphoma and Hodgkin disease
KW - Marrow and stem cell transplant clinical results
KW - Pharmacotherapeutics
UR - http://www.scopus.com/inward/record.url?scp=84925294622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925294622&partnerID=8YFLogxK
U2 - 10.3109/10428194.2013.876634
DO - 10.3109/10428194.2013.876634
M3 - Review article
C2 - 24512319
AN - SCOPUS:84925294622
SN - 1042-8194
VL - 55
SP - 2262
EP - 2270
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -
